02493 邁威生物－Ｂ
MABWELL-B
MABWELL-B
| Register Close | 2026/04/23 IPO Closing in 2 Days |
| Listing Date | 2026/04/28 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Mabwell (Shanghai) Bioscience Co. was founded in 2017, it is a pharmaceutical company in China to innovate in drug development and for its end-to-end capabilities from drug discovery to commercial sales. It mainly focused on developing drugs internally for oncology and age-related diseases, in areas such as oncology, immunology, ophthalmology and orthopedics.
--
The Group has one Core Product 9MW2821 (bulumtatug fuvedotin) (“BFv”), a Nectin cell adhesion molecule 4 (“Nectin-4”) targeting antibody-drug conjugate (“ADC”) (the “Nectin-4 targeting ADC”). In addition, the Group has built a pipeline portfolio consisting of 4 commercialized products and 10 drug candidates (1 in NDA stage, 8 in clinical stage and 1 in preclinical stage) with various modalities.
--
As of April 12, 2026, the Group secured 147 patents and submitted 271 patent applications globally, including 27 patents and 15 patent applications in relation to its Core Product, and has three commercialized biosimilars, namely Mailishu, Maiweijian and Junmaikang that have received marketing approval.
--
The Group sell substantially all of its commercialized drug products in China to third-party distributors, who are its direct customers and are responsible for on-selling and delivering its products generally to hospitals, medical institutions and pharmacies. The Group generated revenue from sales of pharmaceutical products and out-licensing arrangements.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 47.13M H shares |
| No. of International Offer Shares | 42.42M H shares |
| No. of HK Offer Shares | 4.71M H shares |
| Offer Price | $27.64 - $30.71 |
| Stock Code | 2493 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited, Haitong International Capital Limited |
| Underwriter(s) | CLSA Limited, Haitong International Securities Company Limited, China Industrial Securities International Capital Limited, CMB International Capital Limited, CCB International Capital Limited, Guosen Securities (HK) Brokerage Company, Limited, Futu Securities International (Hong Kong) Limited, ABCI Securities Company Limited, Bowlea Securities Limited |
TIME TABLE
| Application Period | Apr 20 (Mon) - noon, Apr 23 (Thu) |
| Price Determination Date | Apr 24 (Fri) |
| Result Announcement Date | On or before Apr 27 (Mon) |
| Result Announcement Date | On or before Apr 27 (Mon) |
| Result Announcement Date | On or before Apr 28 (Tue) |
| Dealings in Shares commence on | Apr 28, 2026. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $27.64 - $30.71 |
| Capitalization | 18.59B - 18.73B |
| NAV / share ($) | $3.21 - $3.52 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 29.18, the net proceeds raised would be HKD 1.26B, of which |
| 56.8% : For the clinical development trials of Core Product, 9MW2821, at various stages for multiple indications |
| 17.7% : R&D of other pipeline products focused on oncology and age-related diseases with significant clinical needs |
| 15.5% : Used for commercialization purposes |
| 10% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).